SciSparc Provides Updates Upon Conclusion of 2021
December 29, 2021
Ryan Allway December 29th, 2021 TEL AVIV, Israel, Dec. 29, 2021 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today provides updates regarding its activities in 2021. SciSparc Ltd. Logo... Read more
SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market
CBD December 20, 2021
Ryan Allway December 20th, 2021 TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCF) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced that its ordinary shares have been approved for listing... Read more
Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug
December 14, 2021
Ryan Allway December 14th, 2021 POTOMAC, Md., December 14, 2021–(BUSINESS WIRE)–(NYSE American: IGC), India Globalization Capital, Inc. (“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s... Read more
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease
November 16, 2021
Ryan Allway November 16th, 2021 Psychedelics The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS... Read more
Ryan Allway May 6th, 2021 Psychedelics VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its... Read more
